Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112,952 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Lin C, DiCioccio RA, Haykal T, McManigle WC, Li Z, Anand SM, Poe JC, Bracken SJ, Jia W, Alyea EP 3rd, Cardones AR, Choi T, Gasparetto C, Grunwald MR, Hennig T, Kang Y, Long GD, Lopez R, Martin M, Minor KK, Quinones VLP, Sung AD, Wiggins K, Chao NJ, Horwitz ME, Rizzieri DA, Sarantopoulos S. Lin C, et al. Among authors: li z. Transplant Cell Ther. 2023 Mar;29(3):179.e1-179.e10. doi: 10.1016/j.jtct.2022.12.015. Epub 2022 Dec 25. Transplant Cell Ther. 2023. PMID: 36577483 Free PMC article. Clinical Trial.
Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.
Rizzieri DA, Crout C, Storms R, Golob J, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Lagoo AS, Morris A, Beaven A, Yang Y, Peterson B, Li Z, Chao NJ. Rizzieri DA, et al. Among authors: li z. Cancer Invest. 2011 Jan;29(1):56-61. doi: 10.3109/07357907.2010.535055. Cancer Invest. 2011. PMID: 21166499 Free PMC article.
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, DeCastro CM, Friedman DR, Diehl LF, Rehder C, Cook H, Daugherty FJ, Matta KM, Weinberg JB, Rizzieri D. Lanasa MC, et al. Among authors: li z. Leuk Lymphoma. 2012 Feb;53(2):218-24. doi: 10.3109/10428194.2011.610012. Epub 2011 Sep 23. Leuk Lymphoma. 2012. PMID: 21827374
Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.
Kanda J, Long GD, Gasparetto C, Horwitz ME, Sullivan KM, Chute JP, Morris A, Shafique M, Li Z, Chao NJ, Rizzieri DA. Kanda J, et al. Among authors: li z. Biol Blood Marrow Transplant. 2014 Feb;20(2):257-63. doi: 10.1016/j.bbmt.2013.11.010. Epub 2013 Nov 20. Biol Blood Marrow Transplant. 2014. PMID: 24269380 Free PMC article.
Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Tuchman SA, Bacon WA, Huang LW, Long G, Rizzieri D, Horwitz M, Chute JP, Sullivan K, Morris Engemann A, Yopp A, Li Z, Corbet K, Chao N, Gasparetto C. Tuchman SA, et al. Among authors: li z. J Clin Apher. 2015 Jun;30(3):176-82. doi: 10.1002/jca.21360. Epub 2014 Oct 8. J Clin Apher. 2015. PMID: 25293363 Free PMC article.
112,952 results
You have reached the last available page of results. Please see the User Guide for more information.